title: Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response.
abstract: ABT-925, a selective dopamine D3 receptor (DRD3) antagonist, was tested in schizophrenia. A DRD3 gene polymorphism results in an S9G amino-acid change that has been associated with lower risk of schizophrenia, higher affinity for dopamine and some antipsychotics, and differential response to some antipsychotics. The effect of S9G genotype on response to ABT-925 was examined. DNA samples (N=117) were collected in a proof-of-concept, double-blind, randomized, placebo-controlled study of ABT-925 (50 or 150 mg QD) in acute exacerbation of schizophrenia. A pre-specified analysis assessed impact of genotype (SS versus SG+GG) on change from baseline to final evaluation for the Positive and Negative Syndrome Scale (PANSS) total score using analysis of covariance with genotype, treatment and genotype-by-treatment interaction as factors, and baseline score as covariate. Significant genotype-by-treatment interaction (P=0.015) was observed for change from baseline to final evaluation for the PANSS total score. Within subgroup analyses showed significant improvement from placebo in the SG+GG group treated with ABT-925 150 mg. More favorable clinical outcomes were observed in patients treated with ABT-925 150 mg who carried the DRD3 G allele than in those who carried the DRD3 SS genotype.
authors.affiliation: Research and Development, AbbVie Inc., North Chicago, IL, USA. anahita.bhathena@abbvie.com
authors.forename: A
authors.initials: A
authors.lastname: Bhathena
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: J B
authors.initials: JB
authors.lastname: Kraft
authors.forename: K B
authors.initials: KB
authors.lastname: Idler
authors.forename: S J
authors.initials: SJ
authors.lastname: Abel
authors.forename: R R
authors.initials: RR
authors.lastname: Holley-Shanks
authors.forename: W Z
authors.initials: WZ
authors.lastname: Robieson
authors.forename: B
authors.initials: B
authors.lastname: Spear
authors.forename: L
authors.initials: L
authors.lastname: Redden
authors.forename: D A
authors.initials: DA
authors.lastname: Katz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000483:Alleles; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011569:Psychiatric Status Rating Scales; D011743:Pyrimidines / Q000627:therapeutic use*; D050637:Receptors, Dopamine D3 / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; C493593:DRD3 protein, human; D018492:Dopamine Antagonists; D010879:Piperazines; D011743:Pyrimidines; D050637:Receptors, Dopamine D3; D002394:Catechol O-Methyltransferase; C585125:ABT-925